---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005944"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T06:55:06.935323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Cocrystal Pharma's Norovirus Antiviral CDI-988 Shows Potent Activity Against Emerging GII.17 Variants

## Summary
- CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
- Company plans to initiate a human norovirus challenge study in 2025 for prevention and treatment.
- Phase 1 study showed favorable safety and tolerability of CDI-988 in healthy adults.
- Norovirus causes ~685 million cases and ~50,000 child deaths annually with $60B societal cost.
- No approved antiviral treatments or vaccines for norovirus exist.

## SEC filing metadata
- accession: 0001641172-25-005944
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/0001641172-25-005944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225005944/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005944
- JSON: https://secwatch.observer/filing/0001641172-25-005944.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.